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The growing data obtained from in vivo studies and clinical trials demonstrated the benefit
of adult stem cells transplantation in diabetes; although an important limit is represented
by their survival after the transplant. To this regard, recent reports suggest that genetic
manipulation of stem cells prior to transplantation can lead to enhanced survival and
better engraftment. The following review proposes to stimulate interest in the role of heme
oxygenase-1 over-expression on transplantation of stem cells in diabetes, focusing on
the clinical potential of heme oxygenase protein and activity to restore tissue damage
and/or to improve the immunomodulatory properties of transplanted stem cells.
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DIABETES AND RELATED COMPLICATIONS
Diabetes mellitus includes a series of metabolic disorders due to the lack or diminished effectiveness
of insulin secretion (Chiang et al., 2014; American Diabetes Association, 2016). Diabetes can be
classified based on its pathogenesis in two distinct classes: the type 1 diabetes, also known as
juvenile diabetes, and type 2 diabetes, also known as adult-type diabetes. Both types of diabetes are
preceded by a period during which it is observed an impaired glucose homeostasis (Roden, 2016).
Prediabetes is an asymptomatic medical condition that does not cause any functional impairment;
patients who are in this situation may evolve toward diabetes in varying degrees on the basis
of genetic and environmental factors. Prediabetic patients are at an increased risk of developing
Type 2 Diabetes Mellitus (Allende-Vigo, 2015). The World Health Organization estimated that 9%
of adults worldwide suffer from diabetes, and the total number is predicted to increase by over
50% over the next 20 years (Fonseca, 2009). The epidemiology of diabetes includes population
growth, urbanization, aging, ethnicity, increased prevalence of obesity, hypertension, and increased
sedentary (Krijnen et al., 2009). Dysfunction of beta cell lead to altered insulin production and
secretion resulting in hyperglycemia and glucose intolerance manifesting to diabetes mellitus.
Diabetes is associated with premature death, coronary artery disease, and myocardial infarction,
stroke, peripheral vascular disease and limb amputation, blindness, kidney failure, and the
requirement for dialysis, as well as in several infrequently occurring complications. Diabetic
complications are classified into two main groups: the acute and the chronic complications. The
former includes diabetic keto-acidosis which is generally encountered in type 1 and nonketotic
hyperosmolar syndrome which is common in type 2 diabetes mellitus. The other types of diabetic
complications refer to the chronic ones, which may involve several organs and representing
the major cause of morbidity and mortality in patients with diabetes mellitus (Tripathi and
Srivastava, 2006). The chronic complications of diabetes have been classified as either vascular or
non-vascular. The vascular diabetic complications are sub-classified into microvascular including
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damage to kidneys, eyes, and nerves. The latter leads to
diabetic foot ulcer developing into gangrene and amputation.
Diabetic ischemic ulcer is an intractable diabetic complication.
Recently, transplantation of stem cells is considered as a possible
new therapeutic strategy for the treatment of diabetic ulcers.
Macrovascular complications are due to damage of the larger
blood vessels through a process known as “atherosclerosis,”
leading to a narrowing of the vessel lumen and consequent
reduction of blood supply in the serving district. Non-vascular
complications include gastroporesis and diarrhea, uropathy, or
sexual dysfunction, and skin manifestations, gum infection,
and complications of eye like cataract and glaucoma (Tripathi
and Srivastava, 2006; Cade, 2008). The treatment of diabetes
mellitus includes diet (Li Volti et al., 2011; Marrazzo et al.,
2014), therapy with insulin and/or oral hypoglycemic agents and
pancreas transplantation or pancreatic islets (Logdberg et al.,
2003). However, because of the limited availability of donor
organs, recent studies have focused on the possibility of using
stem cells for the treatment of DM (Li and Ikehara, 2013).
HEALTH IMPACT OF ADULT STEM CELLS
Multipotent stem cells, which have gradually turned out to play a
key role in regenerative medicine therapies, can be retrieved from
adult tissue, and bone marrow (BM) represents an important
source for these cells. The stem cells derived from BM, as well
as umbilical cord blood or the placenta, are all indicated as
adult stem cells. The BM mainly contains two types of stem
cells: hematopoietic stem cells (HSCs) and mesenchymal stem
cells (MSCs). MSCs have been described for the first time by
Friedenstein et al. as very similar to fibroblast cells capable of
differentiating into cells of the bone tissue (Friedenstein et al.,
1968; Hematti, 2008). The fate of a stem cell is determined by its
niche, or local micro-environment. Stem cells actively contribute
to their environment by secreting cytokines, growth factors
and extracellular matrix molecules that act paracrinally and
autocrinally. MSCs are considered a critical component of the
bone marrow micro-environment, and directly contribute to the
development of hematopoietic stem cells, readily distinguishable
from MSCs by their cell surface markers. MSCs are considered
multipotent stem cells that are capable of self-renewing and
differentiating into different functional cell types. The ease
of isolation, the high migratory capacity, the relatively high
expansion rates, and the ability to avoid the allogeneic responses
after transplantation (Sekiya et al., 2002; Chen et al., 2004;
Fouillard et al., 2007), make them attractive candidates in
regenerative medicine (Pacini, 2014). Recent findings show that
MSCs participate in tissue repair processes through various
mechanisms including the migration into the damaged tissue
(Sordi et al., 2005) and the release of paracrine factors such as
cytokines and other trophic factors (Caplan and Dennis, 2006;
Salomone et al., 2013).
To this regard, recent animal studies and clinical trials have
shown that MSCs are effective in acute myocardial infarction
and chronic heart failure and this effect is related to the
release of paracrine signals involved in the differentiation
of cardiomyocytes, smooth muscle cell, vascular endothelial
cells, and stimulating endogenous repair (Boyle et al., 2010).
Improvements in myocardial function following stem cells
transplantation have been attributed to stem cells differentiation
into cardiomyocytes within host myocardium. However, it has
been demonstrated that few exogenous stem cells actually engraft
and differentiate into cardiomyocyte lineage. Several studies
showed that BM-MSCs secrete cytoprotective molecules that
reduce apoptosis and necrosis (Baraniak and McDevitt, 2010).
Furthermore, it has been demonstrated that resident cardiac
progenitor cells are abundantly present within the myocardium
in niches preferentially located in the atria and apex and in
the ventricle and effectively preserve the integrity of the tissue.
Cardiac progenitor cells appear tomigrate and accumulate within
ischemic and scarred myocardium in order to evoke cardiac
regeneration. It has been shown that MSCs can secrete a number
of chemotactic factors that may contribute to the activation and
migration of cardiac progenitor cells toward areas of injury.
Although, it is widely accepted that MSCs functionality is highly
affected by sex, age, disease, and the pharmacological treatment
of donors, controversies about influence of tissue origins are still
debated. These differences may be related to the influence of a
modified local environment (niche) present in a different site of
the body.
The local microenvironment protects the stem cells and
modify their biological behavior. In that regard, the identification
and characterization of the stem cells niches has been particularly
complex from the time that stem cells are poorly present, and
in some cases are devoid of cellular markers that can allow their
secure identification. Recently studies described that in the bone
marrow, besides MSCs and HSCs, there are different progenitor
cells including the endothelial progenitor cells (EPCs) and the
mesodermal progenitor cells (MPCs). Pacini at al. isolated MPCs
from culture of human bone marrow-derived cells and observed
that MPCs differ from MSCs in terms of their morphology
and in terms of their quiescent status (Pacini et al., 2010).
MPCs have been proven to be capable of generating CFU-
F and of differentiating into mesodermal lineages (adipocytes,
chondrocytes, and osteoblasts), in the presence of appropriate
stimuli, (Pittenger et al., 1999) and through the commitment
into an intermediate cell population which is considered “early
MSCs.” Furthermore, MPCs may differentiate into endothelial
cells when cultured in an appropriate VEGF-containing medium
similar to those used in the differentiation of embryonic cells
(Trombi et al., 2009). Circulating EPCs are regarded as the
cells expressing both stem cell markers and endothelial cell
markers. EPCs circulate in the blood and appear to home
preferentially to sites of vascular or tissue injury, contributing
significantly to both reendothelialization and angiogenesis. Many
evidences suggest that BM-derived EPCs have the potential to
promote angiogenesis in the postnatal period, thus providing
a good rationale for their use in clinical practice for the
treatment of cardiovascular diseases. It has been reported
that transplantation of EPCs derived from healthy human
peripheral blood, significantly increased vascularization, and
improved the survival rate after acute liver injury in mice
(Taniguchi et al., 2006). Thus, therapeutic approaches using
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culture-expanded adult stem cells, including progenitor stem
cells, could successfully promote regeneration of damaged tissues
in cardiovascular diseases.
In addition to these properties, that support the use of stem
cells in regenerative medicine, it must be added the capability
of this cell type to modulate the T cell response and/or to
provide a microenvironment with immunosuppression capacity.
The latter ability of MSCs has generated considerable interest
in the scientific community since this specific feature could be
exploited in the downregulation of the immune response that
occurs in graft-vs.-host-disease and autoimmune diseases such
as multiple sclerosis, type 1 diabetes and rheumatoid arthritis
(Glenn and Whartenby, 2014). During an immune response,
MSCs are known to communicate with the inflammatory micro-
environment. MSCs express a large number of surface molecules
includingmembers of the integrin family and adhesionmolecules
that promote cellular interactions via receptors binding on
immune cells (Najar et al., 2016).
The broad applicability of MSCs in a plethora of metabolic
and degenerative disease models is subsequent partially to the
ability of MSCs to modulate several cellular component of
the innate and adaptive immune system. These features have
attracted significant interest in the field of solid organ transplants
and some studies have been done to evaluate the effect of
the infusion of MSCs simultaneously to organ transplantation
in patients treated with standard immunosuppression protocol.
MSCs cotransplantation prolonged islet graft survival in all
recipients when they also were treated with CTLA4Ig and anti-
CD40L (Takahashi et al., 2014). In NODmice, the administration
of a single infusion of MSCs was able to prevent the onset
of type 1 diabetes and to retard its progression by inhibiting
the accumulation of effector T-cells (Madec et al., 2009). The
immunosuppressive effects ofMSCs are induced by the activation
of several key enzymes, such as nitric oxide synthase, cyclo
oxygenase-2, and Heme Oxygenase (HO)-1 (Hinden et al., 2015).
Interestingly, human MSCs express HO-1 levels, but HO-1
inhibition significantly reduces the suppressive effects of MSCs,
highlighting the key role of HO-1 in the immunosuppression
mediated by human MSCs (Chabannes et al., 2007).
BIOLOGICAL FUNCTIONS OF HEME
OXYGENASE
HO exists in two forms, HO-1, the inducible form, and HO-2, the
constitutive form. Both isoforms degrade heme into biliverdin
with the concurrent release of carbon monoxide (CO) and
iron (Abraham et al., 2016). In mammals, biliverdin is then
reduced by biliverdin reductase to bilirubin (Kapitulnik and
Maines, 2009). Iron, bilirubin, and CO, the three byproducts of
the HO reaction, possess important biological functions. Both
bilirubin and biliverdin have good antioxidant activity and may
exert protective effects both in vivo and in vitro under various
experimental conditions (Stocker et al., 1987; Sacerdoti et al.,
2005). CO may serve as a second messenger in the central
nervous system (Verma et al., 1993), it inhibits endothelial cell
apoptosis through the activation of p38MAPK (Otterbein and
Choi, 2000; Sacerdoti et al., 2005) and acts as a vasodilator
through the stimulation of guanylate cyclase. HO-1 can be
induced by many drugs and chemical agents, including statins,
aspirin, prostaglandins, eicosanoids, and metals (Marrazzo et al.,
2011; Tibullo et al., 2013; Abraham et al., 2016). Furthermore,
several natural antioxidant compounds contained in foods and
plants have been demonstrated to regulate HO-1 levels in various
cellular models (Acquaviva et al., 2009; Vanella et al., 2013, 2016).
HO-2 contributes to basal physiological functions while HO-1
represents the major cytoprotective moiety of the HO system,
by scavenging ROS and preventing apoptosis (Novo et al., 2011;
Burgess et al., 2012; Tibullo et al., 2013). HO may represent a
beneficial target to limit the pathogenesis of obesity, diabetes and
their complications. It is noteworthy that, an excessive increase
in visceral fat is associated with insulin resistance, diabetes and
hypertension. Induction of HO-1 in diabetes has been reported
to restore the functionality of several mitochondrial carriers,
increase Akt phosphorylation and to improve renal function
(Di Noia et al., 2006). In addition, HO-1 upregulation leads to
a decrease in ROS and LDL levels in many diabetes models.
Targeting HO-1 or the products of heme degradation stems
from the finding that over-expression of HO-1 increases insulin
sensitivity, decreases body weight, and reduces proinflammatory
adipokines including TNF-α, IL-6, and MCP-1 (Marino et al.,
2012). A decrease in heme levels, consequent to HO-1 activation,
limits heme availability for the maturation of gp91phox subunit
and assembly of the functional NADPH oxidase which represents
the major source of the superoxide anion (Taille et al., 2004).
THERAPEUTIC POTENTIAL OF HO ON
STEM CELLS TRANSPLANTATION
MSCs could be exploited for the delivery of specific genes for
therapeutic purposes. In this regard, some studies suggest that
genetic modification of MSCs prior to transplantation can lead to
increased survival, improved engraftment and improved cardiac
outcome inmodels of myocardial infarction (Gnecchi et al., 2006;
Wang et al., 2016). Cai at al. demonstrated that pretreatment of
human cardiac stem cells with cobalt protoporphyrin (CoPP),
an HO-1 inducer, enhanced cells survival, and resulted in great
improvement in left ventricular remodeling and in indices of
cardiac function after infarction (Cai et al., 2015). In addition
to that, previous studies suggested that CoPP increases the
survival of cardiomyocytes and restores contractility to adult
cardiomyocytes grafts implanted in vivo as well as protects the
heart from ischemic damage in both normal and diabetes rats
(Cao et al., 2012). The use of stem cells as a potential approach to
treat diabetes may also offer the possibility to selectively deliver
the expression of HO-1 in a cell and organ specific manner
without the need of a viral vector or specific promoters. In
fact, HO-1 induction may be easily achieved by pharmacological
means prior stem cell transplantation in the patients by several
agents. In particular, various chemical compounds have been
used both in vivo and in vitro to induce HO-1 such as SnCl2 or
CoPP. However, there could be some limitations on the possible
use of these compounds into a clinical setting because of the
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metal toxicity. Noteworthy, previous reports showed that natural
polyphenols may be used as good inducers of HO-1 because
of their ability of activating the Nrf2/Keap1 pathway and may
represent a good and safe strategy to induce HO-1 prior to stem
cell transplant (Scapagnini et al., 2002; Marrazzo et al., 2011;
Barbagallo et al., 2013).
Despite the widespread use of hypoglycemic agents, morbidity
and mortality caused by type 1 diabetes mellitus represent
a significant burden for society, both in terms of human
suffering and cost (Logdberg et al., 2003). Transplantation of
pancreatic islets is an important approach to the treatment
of diabetes type 1, but after the transplant procedure, cells
frequently undergo apoptosis causing a dysfunction of the
islets. It has been demonstrated, in vivo, that treatment of the
mouse donor with carbon monoxide, a reaction product of HO-
1, suppresses the proinflammatory response, characterized by
an increase of TNF-α, IL-1β, and MCP-1, in the islets after
transplantation (Wang et al., 2005). Ikehara’s group described
the use of stem cells for the treatment of both type 1 and type
2 diabetes (Ikehara, 2003) by a reduction in the development
of hyperglycemia and hyperinsulinemia in diabetic mice (Than
et al., 1992; Abraham et al., 2008). Chronic hyperglycemia leads
to a reduction of the expression of HO-1 and the total enzyme
activity, resulting in increased levels of superoxide anion, and cell
death (Abraham et al., 2003). Oxidative stress has been shown
to play a key role in the pathogenesis of insulin resistance in
type 2 diabetes and of cardiovascular complications (Wellen
and Hotamisligil, 2005; Ruotsalainen et al., 2008). Previous
report demonstrated that the transplantation of bone marrow
mesenchymal stem cells (BMMSCs) via intra bone marrow-bone
marrow transplantation (IBM-BMT) in conjunction with the
induction of HO-1 ameliorate type 2 diabetes mellitus (Li and
Ikehara, 2013).
Previous studies showed that transplantation of bone marrow
stem cells, including MSCs, but not limited to CD34+ stem
cells, into type 2 diabetic mice restored insulin sensitivity and
improved glucose tolerance (Abraham et al., 2008). Pretreatment
with a HO-1 inducer followed by the IBM-BMT offers great
improvement in diabetes, glucose tolerance, and oxidative stress.
The mechanism by which HO-1 improves the effectiveness of
IBM-BMT is due to a decrease in superoxide levels, which causes
impairment in MSCs function and release of crucial cytokines.
Hyperglycemia-induced reactive oxygen species accumulation
has been postulated to be a central mediator of diabetes
mellitus–induced EPCs dysfunction (Sambuceti et al., 2009).
Several studies demonstrated that EPCs represent an important
contributor to neovascularization, through the secretion of
paracrine angiogenic factors (Urbich et al., 2005). Reduced
number and function of EPCs are causally associated with
diabetes mellitus–induced impairment in vasculogenesis (Tepper
et al., 2002; Sorrentino et al., 2007). A diminished HO-1/AMPK
signaling cascade in EPCs may account in part for impaired
reendothelialization in diabetes mellitus (Li et al., 2012). EPCs
isolated from diabetic mice and transplanted into injured
arteries of recipient diabetic mice, didn’t show a significant
efficacy, whereas the attachment capacity of EPCs isolated from
FIGURE 1 | Schematic representation demonstrating the role of HO-1 in stem cells transplantation.
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diabetic transgenic mice, over expressing AMPK-HO-1 levels,
was comparable to that of EPCs from healthy mice (Li et al.,
2012). Treatment of transgenic diabetic mice with a specific
HO-1 inhibitor (ZnPPIX) abolished the HO-1 mediated effects,
providing a direct evidence that HO-1 upregulation restores
the function of damaged EPCs (Li et al., 2012). Experiments
in vitro revealed that HO-1 is necessary for proper activity
of BM-derived stem cells (BMDCs). Indeed, HO-1-deficient
BMDCs are less viable when exposed to oxidants and display a
weaker proliferation and migration capacity (Grochot-Przeczek
et al., 2014). Similar effects were observed in murine mature
or progenitor endothelial cells (Jozkowicz et al., 2003; Deshane
et al., 2007) and in human endothelium with less active variants
of Hmox1 promoter (Taha et al., 2010). In particular, it has
been also demonstrated a weaker angiogenic potency of HO-1
−/− BMDCs in capillary sprouting assay, confirming the results
obtained earlier in human endothelial cells treated with HO-
1 inhibitors or in murine endothelial cells isolated from HO-1
+/+ or HO-1−/−mice (Grochot-Przeczek et al., 2014). People
with diabetes may be at increased risk of developing acute renal
failure. Furthermore, numerous studies highlighted diabetes as
a major risk factor for the development of acute renal injury
(AKI) in hospitalized patients (Johnson et al., 2015). Several
studies have shown that the BMSCs transplantation may play
a beneficial role following renal ischemic injury, possibly by
the paracrine/autocrine mechanisms, or by trans-differentiation
into the local cell types (Morigi et al., 2004; Qian et al.,
2008; Li et al., 2010). However, after transplantation into the
dysfunctional kidney, BMSCs face a pro-oxidant environment
characterized by hypoxia, oxidative stress, and inflammation
(Mias et al., 2008) that can lead to reduced cell survival and
consequently to a decreased therapeutic effect. The oxidative
stress leads to stress-induced premature senescence, cell death,
and apoptosis of the transplanted BMSCs. Recently, it was
reported that over-expression of HO-1, by gene transfection,
in BMSCs, was able to improve HO-1-BMSCs survival in the
I/R-AKI micro-environment and decrease the levels of MCP-
1, TNF-a, and IL-1, leading to a greater improvement of renal
function compared to BMSCs treatment alone (Liu et al., 2015).
Recently, stem cell transplantation has been considered as a
new therapeutic strategy for diabetic foot ulcers. Hou’s group
demonstrated that the over-expression of HO-1 in BMSCs
promoted angiogenesis and wound healing in diabetic ischemic
ulcers (Hou et al., 2013). In conclusion, these recent studies
demonstrate that induction of HO-1 plays a key role in
stem cell survival during transplantation of adult stem cells
(Figure 1). Thus, HO-1 represents a new target for designing
new compounds with clinical application in the treatment of
diabetes.
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